Avanz Phleum Pratense Maintenance Dose

Status Completed

Clinical Trial Summary

The purpose of the trial is to evaluate the efficacy of two dosing schedules of Avanz SQ+ (Standardised Quality) Phleum pratense compared to placebo in subjects with grass pollen induced allergic rhinoconjunctivitis with or without asthma.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01438827
Study type	Interventional
Source	ALK-Abelló A/S
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	September 2011
Completion date	January 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03850626` - Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
Completed	`NCT03682965` - Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study	Phase 2
Completed	`NCT04541004` - Adolescent Mite Allergy Safety Evaluation	Phase 3
Completed	`NCT02556801` - Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy	Phase 2
Completed	`NCT01966224` - A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects	Phase 1
Completed	`NCT01918956` - PURETHAL Birch RUSH Study	Phase 4
Completed	`NCT01682070` - SUBLIVAC FIX Phleum Pratense DT/DRF	Phase 2
Completed	`NCT01438463` - PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis	Phase 2
Completed	`NCT00985296` - Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC)	N/A
Completed	`NCT02437786` - Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®	Phase 4
Completed	`NCT01740284` - A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine	Phase 3
Completed	`NCT04912076` - S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen	Phase 1
Completed	`NCT03365648` - Efficacy and Safety of Lertal® as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics	N/A
Completed	`NCT05455749` - Effect of holoBLG on Cat Allergic Patients	N/A
Completed	`NCT01707069` - A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid	Phase 1
Completed	`NCT01466465` - Vitamin D and Grass Pollen Specific Immunotherapy	Phase 2
Completed	`NCT01567306` - Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense	Phase 2
Completed	`NCT01490411` - Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis	Phase 2
Completed	`NCT00777374` - Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration	Phase 2
Active, not recruiting	`NCT04502966` - Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction	Phase 2